The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1338
May 17, 2010
View Complete Issue         Table of Contents 2019 
Which TNF Inhibitor for Rheumatoid Arthritis?
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Which TNF Inhibitor for Rheumatoid Arthritis?
May 17, 2010 (Issue: 1338)
The FDA has approved five tumor necrosis factor (TNF) inhibitors for treatment of moderately to severely active rheumatoid arthritis (RA). TNF-α is a pro-inflammatory cytokine involved in the pathogenesis of many systemic inflammatory...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Which TNF Inhibitor for Rheumatoid Arthritis?
Article code: 1338b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.